Jan 31, 2022
In neuromyelitis optica spectrum disorder (NMOSD), no blood tests to evaluate disease activity, attack severity, or therapy impact have been developed. For a study, the researchers determined the effects of inebilizumab...
Read MoreJul 8, 2021
Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) is important in regulating B cell activation. We investigated whether EBI2 expression on B cells is associated with acute attacks in neuromyelitis optica spectrum...
Read MoreJul 5, 2021
When the novel coronavirus disease 2019 (COVID-19) appeared, concerns about its course in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) arose. This study aimed to evaluate the...
Read MoreNov 20, 2020
This study was done to compare the specificity, sensitivity, and diagnostic accuracy of the three different sets of NMOSD criteria in patients presenting with inflammatory disorders of the central nervous system suggestive of...
Read MoreAug 7, 2020
Neuromyelitis optica (NMO) is a central nervous system disorder that affects the eye nerves and spinal cord. Azathioprine is the recommended first-line treatment for NMO, and tocilizumab has been reported to reduce the NMO...
Read More
